These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1974283)

  • 41. Recurrent neuroleptic malignant syndrome in a man with mild mental handicap.
    Bambrick M; Wilson D
    J Intellect Disabil Res; 1992 Aug; 36 ( Pt 4)():377-81. PubMed ID: 1356040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.
    Liu PY; Wu PC; Chen CY; Chen YC
    Gen Hosp Psychiatry; 2011; 33(1):84.e5-7. PubMed ID: 21353143
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Neuroleptic malignant syndrome: a review of literature].
    Crespo Facorro B; Carbonell Masia C
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1995; 23(5):273-8. PubMed ID: 8553925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Further observations on the neuroleptic malignant syndrome.
    Lazarus A; Lipschutz LB
    J Clin Psychopharmacol; 1991 Apr; 11(2):148-9. PubMed ID: 1676039
    [No Abstract]   [Full Text] [Related]  

  • 45. Neuroleptic malignant syndrome (NMS) on neuroleptic withdrawal.
    Corrigan FM; Coulter F; Mackay AV
    Acta Psychiatr Scand; 1990 Sep; 82(3):268-9. PubMed ID: 1978961
    [No Abstract]   [Full Text] [Related]  

  • 46. Atypical neuroleptic malignant syndrome associated with iloperidone administration.
    Guanci N; Aggarwal R; Schleifer S
    Psychosomatics; 2012; 53(6):603-5. PubMed ID: 23157999
    [No Abstract]   [Full Text] [Related]  

  • 47. Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia.
    Aboraya A; Schumacher J; Abdalla E; LePage J; McGhee M; Butcher D; Griffin H; Shahda M
    W V Med J; 2002; 98(2):63-5. PubMed ID: 12048741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Suspected neuroleptic malignant syndrome in a patient receiving clozapine.
    Ganelin L; Lichtenberg PS; Marcus EL; Munter RG
    Ann Pharmacother; 1996 Mar; 30(3):248-50. PubMed ID: 8833560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Diagnostic and therapeutic aspects of neuroleptic malignant syndrome based on 12 cases].
    Sczesni B; Becker H; Schröder J; Bittkau S; von Baumgarten F; Truong DD; Przuntek H
    Wien Klin Wochenschr; 1991; 103(1):21-6. PubMed ID: 1673042
    [No Abstract]   [Full Text] [Related]  

  • 50. Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient.
    Patel MK; Brunetti L
    Am J Health Syst Pharm; 2010 Aug; 67(15):1254-9. PubMed ID: 20651315
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Olanzapine and NMS.
    Hickey C; Stewart C; Lippmann S
    Psychiatr Serv; 1999 Jun; 50(6):836-7. PubMed ID: 10375159
    [No Abstract]   [Full Text] [Related]  

  • 52. [Neuroleptic malignant syndrome].
    Sczesni B; Schröder J; Becker H; Przuntek H
    Wien Klin Wochenschr; 1991; 103(1):1-7. PubMed ID: 1673041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.
    Supe S; Matijević V; Kondić L; Alvir D
    Psychiatr Danub; 2006 Jun; 18(1-2):97-101. PubMed ID: 16804507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atypical (olanzapine) plus conventional (fluphenazine) neuroleptic treatment associated with the neuroleptic malignant syndrome.
    Tofler IT; Ahmed B
    J Clin Psychopharmacol; 2003 Dec; 23(6):672-4. PubMed ID: 14624203
    [No Abstract]   [Full Text] [Related]  

  • 55. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital.
    Gelenberg AJ; Bellinghausen B; Wojcik JD; Falk WE; Sachs GS
    Am J Psychiatry; 1988 Apr; 145(4):517-8. PubMed ID: 2894782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A case of neuroleptic malignant syndrome caused by discontinuation of psychotropic drugs].
    Takahashi Y; Yaguchi M; Yaguchi H; Togashi A; Suzuki M
    Rinsho Shinkeigaku; 2022 Nov; 62(11):850-855. PubMed ID: 36288965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroleptic malignant syndrome.
    Koponen H; Repo E; Lepola U
    Biol Psychiatry; 1988 Dec; 24(8):943-5. PubMed ID: 2906807
    [No Abstract]   [Full Text] [Related]  

  • 58. Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge.
    Huang TL
    Chang Gung Med J; 2001 Aug; 24(8):522-5. PubMed ID: 11601195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Possible neuroleptic malignant syndrome during paliperidone administration: a case report.
    Mantas C; Kalabokis G; Goulia P; Tourlakopoulos A; Hyphantis T; Mavreas V
    J Clin Psychopharmacol; 2010 Feb; 30(1):89-91. PubMed ID: 20075663
    [No Abstract]   [Full Text] [Related]  

  • 60. Haloperidol-induced neuroleptic malignant syndrome complicated by hyperosmolar hyperglycemic state.
    Rock W; Elias M; Lev A; Saliba WR
    Am J Emerg Med; 2009 Oct; 27(8):1018.e1-3. PubMed ID: 19857430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.